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respiratory product class. Using a dynamic price development graph, the model 
provides explanations for price changes at re-referencing time-points. The model 
clearly demonstrates that Greece leaving the EU will have a significant impact on 
price and revenue across markets, demonstrating the spill-over caused by interna-
tional referencing. ConClusions: The impact of Grexit goes well beyond Greece, 
directly affecting pharmaceutical price and revenue throughout Europe. PRISM 
can be used to assist manufacturers in developing a comprehensive pricing strat-
egy and facilitate dialog with governments operating within fiscally constrained 
environments. The model can also be used to test future scenarios as emerging 
markets are increasingly adopting reference pricing.
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objeCtives: This study sought to identify disease- and patient-specific charac-
teristics impacting on disease progression and outcomes, and to determine key 
attributes to be used in developing a conceptual model of multiple myeloma 
(MM). Methods: English language studies reporting MM attributes and their 
association with disease progression and outcomes were identified from Embase 
and Medline (2004–2014) and congress abstracts (2012–2014) in a systematic litera-
ture review (SLR). A second SLR of treatment guidelines, economic models, health 
technology reports and studies on the burden of MM was also used. An attribute 
was defined as a metric or characteristic of MM that plays a potential role in the 
disease process. These attributes can be explanatory (e.g. patient characteristics) or 
dependant (e.g. survival). Results: From both SLRs, 95 MM attributes were identi-
fied. These were grouped into disease characteristics (e.g. light chains, International 
Staging System [ISS] stage, bone marrow plasma cells, extramedullary disease, 
karyotypic abnormalities), genetic factors [e.g. t(4;14), del(13p), del(17p), hypodip-
loidy, hyperdiploidy], patient characteristics (e.g. age, serum lactate dehydrogenase, 
gender, Eastern Cooperative Oncology Group performance status, comorbidities), 
outcomes (e.g. overall survival), quality of life and symptoms (e.g. pain, fatigue, 
weakness, bone fractures, infection). Attributes were then categorised as explana-
tory or dependent variables. Age, serum lactate dehydrogenase, light chains and 
M protein were among the most common explanatory variables in the literature. 
The most commonly reported dependent variable was overall survival, followed by 
quality of life. None of the studies presented a comprehensive set of determinants of 
disease progression and outcomes. ConClusions: MM is a heterogeneous condi-
tion and it is not yet clear which attributes play a key role in determining disease 
progression and survival. The next step in developing the conceptual model for MM 
is to ask physicians to validate the potential attributes identified and to clarify the 
relationships between validated attributes.
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objeCtives: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been applied to data with treatment switching, despite simulation studies showing 
these to drastically underestimate the underlying treatment effect. Therefore, before 
these studies are included in secondary analyses, the data must be re-analysed 
appropriately. When only summary data are available, individual patient level data 
can be reconstructed using a simulation approach. Given patients switch on disease 
progression, their progression time is assumed equivalent to their switch time. 
Simulating this effectively requires an illness-death modelling framework; the pro-
cess of which is the aim of this research. Methods: An example was used, where 
Kaplan-Meier curves for all three transition rates were available. The coordinates 
were extracted digitally from these scanned survival curves, and used to model 
the times for each transition. Many datasets were created, where the times for the 
transitions were simulated from the respective models. ITT summary statistics 
were calculated for each dataset; then averaged over. Examples with increasingly 
less information on which to estimate the transition rates were also systematically 
investigated. Results: When information on transition rates is available, the pro-
cess is easy to implement; giving data that are, on average, broadly representative 
of the original dataset with median survival times and overall survival hazard ratio 
differing by less than 10% and 0.05 respectively. As the information becomes more 
limited, the process requires additional assumptions, and ultimately may not be 
feasible. ConClusions: Using an illness-death modelling framework to simulate 
individual patient level data is affected by the information available to the analyst. 
However, this approach is important, when addressing treatment switching where 
only summary data are available, as the relationship between time to progression 
and overall survival is modelled correctly.
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objeCtives: Over the past five years, the prevalence and incidence of HIV in Russian 
Federation have increased dramatically. The application of global Markov models, 
and cost conditions applied in Italy, the use of DMF is economically sustainable 
for the NHS. Plausibly, the introduction and usage of this new therapy in RRMS 
patients will ensure clinical benefits for patients without resulting in additional 
costs for the NHS.
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objeCtives: Ministry of Health of Russian Federation announced the support of 
innovative development of pharmaceutical industry. In accordance with these plans, 
we aimed to develop a methodology for quantitative assessment of therapeutic 
value of innovative medical technologies in a multi-criteria decision analysis man-
ner. Methods: The questionnaire was developed during pilot survey (10 experts). 
Then 248 respondents assessed criteria significance (weights) of 14 features of an 
innovative drug and 7 features of a relevant disease. Also they estimated scale’s val-
ues. The respondents were medical practitioners and decision makers in healthcare. 
Results of the survey were analyzed using statistical methods. Results: The most 
valuable features are clinical efficacy and clinical safety with the weights of 9.77% 
and 9.08%, respectively. Absence of effective treatment of the disease, mortality and 
influence on quality of life also are among the valuable features with the weights 
of 8.08%, 7.72% and 7.47%, respectively. Minimal weights have new manufacturing 
technique of the drug (0.69%) and new drug formulation (0.03%). ConClusions: 
Significant and non-significant features of an innovative medical technology and 
disease for which it is intended in terms of therapeutic value were identified. We 
plan to optimize set of criteria and scales and then to assess reliability and validity 
of the developed instrument. This methodology being incorporated in the system 
of evaluation of medical technologies and combined with other methods of analy-
ses will help decision-making regarding innovative drugs in Russia become more 
harmonious and transparent.
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objeCtives: The cost-effectiveness of screening interventions is typically exam-
ined using simulation models. These permit comparisons of multiple screening 
strategies. Cost-effectiveness estimates from such models depend, in part, on what 
alternatives analysts choose to compare and how the simulation results are inter-
preted. Sometimes the comparisons and interpretations made are inappropriate, 
which can obscure evidence and lead to the wrong policy conclusions. The objective 
of this study is to explain eight simple steps that analysts can take to avoid these 
problems. Methods: We use examples from the literature to show how these 
problems can arise and to explain how they can be avoided. The examples chosen 
are from a recent systematic review of the cost-effectiveness of cervical screen-
ing. Results: The eight recommendations are: (i) report costs and effects, rather 
than just incremental cost-effectiveness ratios (ICERs); (ii) present a cost-effec-
tiveness plane; (iii) report cost and effects for all strategies, not just those on the 
efficient frontier; (iv) do not report ICERs for dominated strategies; (v) report costs 
and effects to sufficient significant figures; (vi) include all simulated strategies in 
the basecase analysis; (vii) do not report ICERs for strategies for which it is antici-
pated the inclusion of additional strategies would lead to significant changes in 
the estimated ratio; (viii) when there are multiple factors to vary in a screening 
programme, only vary these factors one at a time when creating alternative strat-
egies. ConClusions: The cost-effectiveness estimates from simulation models 
are particularly dependent on the choices taken by analysts regarding both the 
modelling of alternatives and the interpretation of the cost and effects estimates. 
Although the analytical flaws informing our recommendations might seem obvious, 
they occur with surprising frequency in the literature. The simple eight-item list 
presented here will support better use of screening models in identifying optimal 
policy choices.
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objeCtives: The possibility of Greece leaving the European Union (Grexit) is 
well-publicized, but its impact on the pharmaceutical industry has not been fully 
determined. Majority of established markets use pricing rules that reference 
products both across (international reference pricing; IRP) and within (thera-
peutic reference pricing; TRP) country-lines. IRP and TRP are used as effective 
measures to control price of pharmaceutical products. There is a growing need 
to understand how Grexit will impact these mechanisms through direct or indi-
rect means. Methods: Navigant’s Price and Revenue Impact Simulation Model 
(PRISM), which simulates the impact of IRP and TRP, as well as parallel trade and 
generic entry, was used to quantitatively assess the impact on drug prices across 
50 markets in the EU, North America, Latam, MENA-CIS and Asia. Respiratory 
products were analysed as a class to prevent a biased analysis towards particular 
pharmaceutical companies. Two potential scenarios were analysed with respect 
to Grexit: Markets referencing Greece switch referencing to Slovakia, a replace-
ment low-priced Euro currency Mandatory price cut in Greece resulting from a 
currency shift to the Greek Drachma Results: Outputs of the analysis include 
impact on price, revenue and net present value as well as parallel trade of the 
